Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

and we are on track to announce top line results in the fourth quarter of this year. We believe tezampanel represents a potentially new and promising alternative to current treatments for not only migraine but also other pain conditions. Obtaining multiple dose safety and tolerability data will allow us to plan future studies in those chronic painful conditions."

In five Phase IIa, placebo-controlled trials, tezampanel demonstrated proof of concept in multiple pain models. In a placebo and active-controlled clinical trial in patients with acute migraine, the compound, administered intravenously, achieved statistical significance on all primary and secondary endpoints traditionally required for regulatory approval. These endpoints included pain relief at two hours, pain-free at two hours and relief of nausea, photophobia and phonophobia.

About AK Receptor Antagonists

AK receptors are part of the glutamate biological pathway that transmits pain signals to the brain. In addition, these receptors play a critical role in the development of central sensitization phenomena -- a key component of many pain syndromes, including migraine and persistent pain states such as chronic neuropathic pain. AK receptor antagonists selectively bind to certain AK receptors to block transmission of pain signals mediated through the activation of a subtype of glutamate receptors. Because they do not block opioid receptors or constrict blood vessels, the safety profile of AK antagonists may offer important advantages over existing drugs to treat migraine and other pain conditions.

About TorreyPines Therapeutics

TorreyPines Therapeutics, Inc. is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel small molecules to treat diseases and disorders of the central nervous system (CNS). Led by an accomplished management team, TorreyPines is leveraging novel drug targets and technologies to potentially deliver
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... DIEGO y PARÍS, 24 de mayo ... VOLC ), un destacado desarrollador y fabricante de ... mejorar la diagnosis y tratamiento de la enfermedad ... preliminares del ensayo ADVISE ( Ad enosine ... E valuation) II durante la sesión de ...
(Date:5/23/2013)... 2013 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... President and Chief Executive Officer of Neurocrine Biosciences, will be ... Health Care Conference in Boston.   The live ... Eastern Time / 8:20 a.m. Pacific Time.  The presentation will ... at http://www.neurocrine.com . If you are ...
(Date:5/23/2013)... THOUSAND OAKS, Calif. , May 23, 2013 ... Deutsche Bank 38 th Annual  Healthcare Conference on Thursday, ... Boston , beginning at 9:20 a.m. Eastern Daylight ... Investor Relations at Amgen, will present at the conference. Live ... Calendar on Amgen,s website, www.amgen.com , under Investors. A ...
Breaking Medicine Technology:Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6
... Aug. 2, 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ... completion of a clinical study that measured lorcaserin concentrations in ... The study was conducted to provide additional data that may ... of brain astrocytoma in male rats. Using the results of ...
... 2011 SI-BONE, Inc. (San Jose, California), a medical device ... joint, announced today that it is launching an intensive clinical ... initiative to generate a substantial body of clinical and economic ... this effort is MISSION ( M inimally I nvasive ...
Cached Medicine Technology:Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 2Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 3Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 4Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 5Arena and Eisai Announce Completion of Study Measuring Lorcaserin Concentrations in Human Cerebrospinal Fluid and Related Analyses 6SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 2SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 3SI-BONE Announces Global Clinical Strategy for Minimally Invasive iFuse Sacroiliac Joint Fusion 4
(Date:5/23/2013)... Mayo Clinic researchers have used next generation genomic analysis ... cancer tumors have similar genetic origins, which may help ... in the journal Cancer Research . , "This ... next generation sequencing in adjacent Gleason patterns in the ... in pathology," says ,John Cheville, M.D., Mayo Clinic pathologist ...
(Date:5/23/2013)... Transvaginal mesh lawsuit claims ... move forward in a federal multidistrict litigation underway in ... Liebhard LLP reports. In an Order issued on ... Bard to seal emails that included supplier information the ... proprietary information about its suppliers. The emails were filed ...
(Date:5/23/2013)... 2013 The vast majority of Americans ... control over their level of physical activity, the healthfulness ... are actually taking that control. Those are among ... Foundation’s 2013 Food & Health Survey. , According to ... to have “a great deal of control” or “complete ...
(Date:5/23/2013)... On April 29th, 2013, UV Technologies ... of H7N9 cases and deaths. The headline read, " UV ... Subside in Northern Hemisphere as Available Daylight Increases .” In ... reported. , Quoting Kevin McGuire, president of UV Technologies, ... budding in the spring and leaves changing in the fall. ...
(Date:5/23/2013)... Cheap Concert Tickets announces that Paul ... at stadiums throughout North America. This well known ticket ... concert tickets to help McCartney fans see Sir Paul live ... states that she is also offering the customer appreciation code ... a baby boomer, she is also a huge McCartney fan ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic genomic analysis lends insight to prostate cancer 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 2Health News:Transvaginal Mesh Lawsuits Move Forward, as Bernstein Liebhard LLP Notes New Order in Federal C.R. Bard Mesh Implant Lawsuits 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2
... Journal of Clinical Dentistry Demonstrate, Significant Cavity-Fighting ... N.Y. and STONY BROOK, N.Y., April 8, 2008 ... announced today that,new data published in the most ... the effects of a new chewable mint in ...
... Three-year demonstration project will test effectiveness of ... of chronic illness in the,Medicare population, ... Board: HFIT) announced today it is working ... of Pfizer Inc., as part of a,three-year ...
... Huckabee Share Behavior Change Successes ... and Discuss Healthcare Strategies and Trends, PALM SPRINGS, ... in scalable behavior change interventions with outcomes,kicked off ENGAGE ... 250 industry experts and leading employers and health plans,throughout ...
... be the greatest advance in waking up since coffee, ... wake up,in the morning feeling refreshed and ready to go, ... performance to spousal,relations and even driving ability. Fortunately, a unique ... a pill you take before,bedtime that will help you to ...
... 2008 Take a look in your,medicine cabinet ... so, are,you contributing to the nation,s dramatic increase ... National Drug Control,Strategies Report, 71 percent of prescription ... friends. Among 12- to 13-year-olds,prescription drug abuse actually ...
... The appearance of a cold sore is,a sign ... more serious,illnesses emerge, according to John Sherman, ND, noted ... Worldwide, between 80% and 90% of the adult population ... according to Dr. Sherman, who,is the author of The ...
Cached Medicine News:Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 2Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 3Health News:Cavities in Children Reduced Over 60 Percent by New Experimental Chewable Mints 4Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 2Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 3Health News:HealthFitness Teams with Pfizer Health Solutions to Implement CMS Senior Risk Reduction Demonstration Project 4Health News:HealthMedia Kicks Off ENGAGE Conference 2Health News:HealthMedia Kicks Off ENGAGE Conference 3Health News:Tired Mother Invents Pill to Wake You Up On Time 2Health News:Prescription Drug Abuse Threatens Availability of Pain Medication 2Health News:A Cold Sore Is Often A Warning Sign of Deeper Health Issues, Expert Says 2